🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the fight against drug-resistant strains of the infection, according to researchers.

A Worldwide Challenge

The sexually transmitted infection are on the rise worldwide, with data suggesting more than 82 million instances each year. Notably increased rates are seen in Africa and countries within the WHO's designated area, which spans from Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune advancement in the reality of growing infection rates, escalating drug resistance and the extremely scarce available drugs currently available.”

Medical experts are increasingly worried about the rise in antibiotic-resistant strains. The WHO has classified it as a "critical concern". Ongoing monitoring showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Drugs Gain Approval

Zoliflodacin, also known as Nuzolvence, was approved by the US Food and Drug Administration in December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists hope that focused deployment of this new drug will help slow the development of resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This medication, which is additionally indicated for urinary tract infections, was shown in trials to be able to combat superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to develop it.

“This approval marks a significant shift in the management of highly resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Testing Data and Worldwide Availability

Based on findings detailed in a major medical journal, the new drug cured more than 90% of uncomplicated infections. This places it at an comparable level with the existing first-line therapy, which involves a dual-drug approach. The trial included over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the rights to make available and distribute the drug in a wide range of low-income and middle-income countries.

Clinicians directly involved have expressed hope. The availability of a one-pill regimen like this is seen as a "game-changer" for managing the epidemic. This is considered essential to lessen the impact of the illness for people and to halt the transmission of highly drug-resistant gonorrhoea worldwide.